全文获取类型
收费全文 | 275篇 |
免费 | 20篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 5篇 |
妇产科学 | 7篇 |
基础医学 | 16篇 |
口腔科学 | 1篇 |
临床医学 | 100篇 |
内科学 | 79篇 |
皮肤病学 | 17篇 |
神经病学 | 1篇 |
特种医学 | 1篇 |
外科学 | 25篇 |
综合类 | 1篇 |
预防医学 | 14篇 |
药学 | 17篇 |
肿瘤学 | 2篇 |
出版年
2022年 | 5篇 |
2021年 | 3篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 9篇 |
2014年 | 13篇 |
2013年 | 10篇 |
2012年 | 3篇 |
2011年 | 3篇 |
2010年 | 7篇 |
2009年 | 20篇 |
2008年 | 4篇 |
2007年 | 9篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 3篇 |
2003年 | 7篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1999年 | 9篇 |
1998年 | 13篇 |
1997年 | 13篇 |
1996年 | 11篇 |
1995年 | 18篇 |
1994年 | 9篇 |
1993年 | 8篇 |
1992年 | 7篇 |
1991年 | 5篇 |
1990年 | 9篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1981年 | 4篇 |
1979年 | 3篇 |
1976年 | 2篇 |
1974年 | 1篇 |
1969年 | 1篇 |
1964年 | 1篇 |
1963年 | 1篇 |
1961年 | 3篇 |
1959年 | 1篇 |
1958年 | 5篇 |
1957年 | 5篇 |
1956年 | 4篇 |
1955年 | 3篇 |
1949年 | 1篇 |
排序方式: 共有295条查询结果,搜索用时 15 毫秒
1.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
2.
GIUSEPPE PERSEO MAURO GIGLI ROBERTO DE CASTIGLIONE 《Chemical biology & drug design》1987,29(4):478-485
The synthesis of TPH-13 (Glp-Glu-Lys-Pro-Tyr-Trp-Pro-Pro-Pro-Ile-Tyr-Pro-Met-OH), a tridecapeptide isolated from the skin of the South American frog Phyllomedusa rohdei, is described and alternative approaches are discussed. 相似文献
3.
Autoantibodies against β1‐Adrenergic Receptors: Response to Cardiac Resynchronization Therapy and Renal Function
下载免费PDF全文
![点击此处可从《Pacing and clinical electrophysiology : PACE》网站下载免费的PDF全文](/ch/ext_images/free.gif)
ANTONIO MICHELUCCI M.D. MARIO MILCO D'ELIOS M.D. ELENA STICCHI Ph.D. PAOLO PIERAGNOLI M.D. GIUSEPPE RICCIARDI M.D. CINZIA FATINI Ph.D. MARISA BENAGIANO Ph.D. ELENA NICCOLAI Ph.D. ALESSIA GRASSI M.Sc. PAOLA ATTANÀ M.D. MARTINA NESTI M.D. GINO GRIFONI M.D. LUIGI PADELETTI M.D. ROSANNA ABBATE M.D. DOMENICO PRISCO M.D. 《Pacing and clinical electrophysiology : PACE》2016,39(1):65-72
4.
Impact on Prognosis of Periprocedural Myocardial Infarction after Percutaneous Coronary Intervention
5.
CORNELIO UDERZO MARIA GRAZIA VALSECCHI ADRIANA BALDUZZI GIORGIO DINI ROBERTO MINIERO FRANCO LOCATELLI ROBERTO RONDELLI ANDREA PESSION WILLIAM ARCESE ANDREA BACIGALUPO PAOLA POLCHI MARINO ANDOLINA CHIARA MESSINA VALENTINO CONTER MAURIZIO ARICÓ STEFANIA GALIMBERTI & GIUSEPPE MASERA 《British journal of haematology》1997,96(2):387-394
We compared the outcome of children with high-risk acute lymphoblastic leukaemia (HR-ALL) in first complete remission (first CR) treated with chemotherapy (CHEMO) or with allogeneic bone marrow transplantation (BMT) in a multicentre study. All children treated by the Italian Paediatric Haematology Oncology Association for HR-ALL in first CR between 1986 and 1994 were eligible for the study. 30 children were given BMT at a median of 4 months from first CR, with preparative regimens including total-body irradiation ( n =25/30). 130 matched controls for BMT patients were identified among 397 HR-ALL CHEMO patients. Matching on main prognostic factors and duration of first CR was adopted to control the selection and time-to-transplant biases. The comparative analysis was based on the results of a stratified Cox model. The estimated hazard ratios of BMT versus CHEMO at 6 months, 1 year and 2 years after CR were 1.38 (CI 0.59–3.24), 0.69 (CI 0.27–1.77) and 0.35 (CI 0.06–1{\raise 5mu ..91), with an overall non-significant difference between the two groups ( P = 0.34). With a median follow-up of 4 years, the disease-free survival was 58.5% (SE 9.3) in the BMT group and 47.7% (SE 4.8) in the CHEMO group, at 4 years from CR. Non-leukaemic death occurred in 4% of CHEMO and 10% of BMT patients. In the BMT group the estimated cumulative incidence of relapse at 1.5 years from CR was 31.5% (SE 8.8) and did not change thereafter, whereas in the CHEMO group the corresponding figure was 29.2% (SE 4.1) and the incidence continued to increase thereafter (48.2% (SE 4.8) at 4 years from CR). The results of this study suggest that, with respect to the CHEMO group, the higher risk of early failure in the BMT group is outweighed by the lower risk of relapse after 1 year. Results prompt the need for a prospective study, in order to demonstrate the likely advantage of BMT in HR childhood ALL in first CR. 相似文献
6.
FABIO PIZZA KEIVAN K. MOGHADAM STEFANO VANDI STEFANIA DETTO FRANCESCA POLI EMMANUEL MIGNOT RAFFAELE FERRI GIUSEPPE PLAZZI 《Journal of sleep research》2013,22(1):32-40
In the diagnostic work‐up of hypersomnias of central origin, the complaint of excessive daytime sleepiness should be objectively confirmed by MSLT findings. Indeed, the features and diagnostic utility of spontaneous daytime sleep at 24 h continuous polysomnography (PSG) have never been investigated. We compared daytime PSG features to MSLT data in 98 consecutive patients presenting with excessive daytime sleepiness and with a final diagnosis of narcolepsy with cataplexy/hypocretin deficiency (n = 39), narcolepsy without cataplexy (n = 7), idiopathic hypersomnia without long sleep time (n = 19), and ‘hypersomnia’ with normal sleep latency at MSLT (n = 33). Daytime sleep time was significantly higher in narcolepsy‐cataplexy but similar in the other groups. Receiver operating characteristics (ROC) curves showed that the number of naps during daytime PSG predicted a mean sleep latency ≤8 min at MSLT with an area under the curve of 0.67 ± 0.05 (P = 0.005). The number of daytime sleep‐onset REM periods (SOREMPs) in spontaneous naps strikingly predicted the scheduled occurrence of two or more SOREMPs at MSLT, with an area under the ROC curve of 0.93 ± 0.03 (P < 10?12). One spontaneous SOREMP during daytime had a sensitivity of 96% with specificity of 74%, whereas two SOREMPs had a sensitivity of 75%, with a specificity of 95% for a pathological REM sleep propensity at MSLT. The features of spontaneous daytime sleep well correlated with MSLT findings. Notably, the occurrence of multiple spontaneous SOREMPs during daytime clearly identified patients with narcolepsy, as well as during the MSLT. 相似文献
7.
Wireless Ultrasound Guidance for Femoral Venous Cannulation in Electrophysiology: Impact on Safety,Efficacy, and Procedural Delay
下载免费PDF全文
![点击此处可从《Pacing and clinical electrophysiology : PACE》网站下载免费的PDF全文](/ch/ext_images/free.gif)
DANIEL RODRÍGUEZ MUÑOZ M.D. EDUARDO FRANCO DÍEZ M.D. JAVIER MORENO M.D. Ph.D. GIUSEPPE LUMIA M.D. ALEJANDRA CARBONELL SAN ROMÁN M.D. TERESA SEGURA DE LA CAL M.D. ROBERTO MATÍA FRANCÉS M.D. Ph.D. ANTONIO HERNÁNDEZ MADRID M.D. Ph.D. JOSÉ LUIS ZAMORANO GÓMEZ M.D. Ph.D. 《Pacing and clinical electrophysiology : PACE》2015,38(9):1058-1065
8.
GIULIO CONTE M.D. CARLO DE ASMUNDIS M.D. Ph.D. JUAN SIEIRA M.D. MOISES LEVINSTEIN M.D. GIAN‐BATTISTA CHIERCHIA M.D. GIACOMO DI GIOVANNI M.D. GIANNIS BALTOGIANNIS M.D. GIUSEPPE CICONTE M.D. YUKIO SAITOH M.D. RUBEN CASADO‐ARROYO M.D. GUDRUN PAPPAERT R.N. PEDRO BRUGADA M.D. Ph.D. 《Journal of cardiovascular electrophysiology》2014,25(5):514-519
9.
MICHAEL S. LEE M.D. JARED OYAMA M.D. ZAHID IQBAL M.D. GIUSEPPE TARANTINI M.D. 《Journal of interventional cardiology》2014,27(1):58-62
Objectives
We evaluated the safety and efficacy of low‐dose heparin (40 IU/kg) for elective percutaneous coronary intervention (PCI).Background
Current guidelines recommend a 70–100 IU/kg bolus of heparin for elective PCI, but this dose may be associated with increased bleeding risk. Low‐dose heparin may have an advantage in this regard, but has not been well studied.Methods
From January 2008 to October 2012, 300 patients underwent elective transfemoral PCI and were treated with an initial bolus of 40 IU/kg of heparin at the UCLA Medical Center. Dual antiplatelet therapy with clopidogrel and aspirin was administered prior to or just after diagnostic coronary angiography. The primary end‐point was the composite of cardiac death, myocardial infarction, urgent target vessel revascularization for ischemia, or major bleeding within 30 days after PCI.Results
The mean activating clotting time was 233 ± 28 seconds. The primary end‐point occurred in 2.3%. The cardiac death rate was 0.3% but was not related to the PCI. The myocardial infarction rate was 1.3%. Urgent target vessel revascularization occurred in 1 patient (0.3%). The major bleeding rate was 0.3%. No stent thrombosis occurred.Conclusion
Using a lower dose of heparin with dual antiplatelet therapy is safe and is associated with a low bleeding risk after transfemoral PCI while providing suppression of ischemic events. This may also represent a cost savings compared with other antithrombotic strategies. A randomized clinical trial comparing low‐dose heparin with bivalirudin in patients is required to determine the optimal anticoagulation strategy. (J Interven Cardiol 2014;27:58–62)10.